Literature DB >> 31017622

Evaluation of Ivermectin vs Permethrin for Treating Scabies-Summary of a Cochrane Review.

Stefanie Rosumeck1, Alexander Nast1, Corinna Dressler1.   

Abstract

CLINICAL QUESTION: Is the use of ivermectin in patients infested with scabies associated with improved clinical and safety outcomes compared with permethrin? BOTTOM LINE: Both ivermectin and permethrin treatment were associated with high clearance rates. There is low-certainty evidence that ivermectin was associated with slightly lower rates of complete clearance after 1 week compared with permethrin, 5%, cream (relative risk [RR], 0.65; 95% CI, 0.54-0.78). After 2 weeks, there was no difference in efficacy (RR, 0.91; 95% CI, 0.76-1.08; low-certainty evidence), or in the number of participants with adverse events (week 4: RR, 1.30; 95% CI, 0.35-4.83; low-certainty evidence).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31017622     DOI: 10.1001/jamadermatol.2019.0279

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  4 in total

Review 1.  Scabies: Epidemiology, Diagnosis, and Treatment.

Authors:  Cord Sunderkötter; Johannes Wohlrab; Henning Hamm
Journal:  Dtsch Arztebl Int       Date:  2021-10-15       Impact factor: 8.251

2.  Erythrodermic scabies in an immunocompetent patient.

Authors:  Ronan Talty; Goran Micevic; William Damsky; Brett A King
Journal:  JAAD Case Rep       Date:  2022-09-08

3.  Control of scabies in a tribal community using mass screening and treatment with oral ivermectin -A cluster randomized controlled trial in Gadchiroli, India.

Authors:  Priyamadhaba Behera; Hrishikesh Munshi; Yogeshwar Kalkonde; Mahesh Deshmukh; Abhay Bang
Journal:  PLoS Negl Trop Dis       Date:  2021-04-16

4.  Management of common scabies and postscabetic itch in adults: Lessons learned from a single-center retrospective cohort study.

Authors:  Le Wen Chiu; Timothy G Berger; Aileen Y Chang
Journal:  Int J Womens Dermatol       Date:  2021-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.